Vanesa López-Valverde

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

Sara A. Hurvitz, Miguel Martín, Kyung Hae Jung et al. · Journal of Clinical Oncology · 2019 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17

Combination of Ca²⁺‐activated K⁺ channel blockers inhibits acetylcholine‐evoked nitric oxide release in rat superior mesenteric artery

Vanesa López-Valverde, Luis Rivera, Alun D. Hughes et al. · British Journal of Pharmacology · 2006 · 79 citations · Full text

Life Sciences, Biophysics, Physiology +14

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

Suzanne Leijen, Mark R. Middleton, Patricia Tresca et al. · Clinical Cancer Research · 2012 · 71 citations

Medicine, Oncology, Pharmacology +17

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

Sanne Lysbet de Haas, Dennis J. Slamon, Miguel Martín et al. · Breast Cancer Research · 2023 · 43 citations · Full text

Medicine, Oncology, Pharmacology +17

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

Sara A. Hurvitz, Aditya Bardia, Vanesa Quiroga et al. · The Lancet Oncology · 2023 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17